New Jersey S 191: Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

Bill Text

(Sponsorship Updated As Of: 9/12/2024)
SENATE, No. 191

STATE OF NEW JERSEY
221st LEGISLATURE

PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION

Sponsored by:
Senator VINCENT J. POLISTINA
District 2 (Atlantic)

Co-Sponsored by:
Senator Steinhardt

SYNOPSIS
Classifies xylazine as Schedule III controlled dangerous substance under
certain circumstances.

CURRENT VERSION OF TEXT
Introduced Pending Technical Review by Legislative Counsel.

S191 POLISTINA
2

EXPLANATION – Matter enclosed in bold-faced brackets [thus] in the above bill is
not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

AN ACT concerning xylazine and amending P.L.1970, c.226. 1
2
BE IT ENACTED by the Senate and General Assembly of the State 3
of New Jersey: 4
5
1. Section 7 of P.L.1970, c.226 (C.24:21-7) is amended to read 6
as follows: 7
7. Schedule III. 8
a. Tests. The director shall place a substance in Schedule III if 9
he finds that the substance: (1) has a potential for abuse less than 10
the substances listed in Schedules I and II; (2) has currently 11
accepted medical use in treatment in the United States; and (3) 12
abuse may lead to moderate or low physical dependence or high 13
psychological dependence. 14
b. The controlled dangerous substances listed in this section are 15
included in Schedule III, subject to any revision and republishing 16
by the director pursuant to subsection d. of section 3 of P.L.1970, 17
c.226 (C.24:21-3), and except to the extent provided in any other 18
schedule. 19
c. Any material, compound, mixture, or preparation which 20
contains any quantity of the following substances associated with a 21
stimulant effect on the central nervous system: 22
(1) Amphetamine, its salts, optical isomers, and salts of its 23
optical isomers. 24
(2) Phenmetrazine and its salts. 25
(3) Any substance which contains any quantity of 26
methamphetamine, including its salts, isomers, and salts of isomers. 27
(4) Methylphenidate. 28
d. Any material, compound, mixture, or preparation which 29
contains any quantity of the following substances having a potential 30
for abuse associated with a depressant effect on the central nervous 31
system: 32
(1) Any substance which contains any quantity of a derivative of 33
barbituric acid, or any salt of a derivative of barbituric acid, except 34
those substances which are specifically listed in other schedules 35
(2) Chlorhexadol 36
(3) Glutethimide 37
(4) Lysergic acid 38
(5) Lysergic acid amide 39
(6) Methyprylon 40
(7) Phencyclidine 41
(8) Sulfondiethylmethane 42
(9) Sulfonethylmethane 43
(10) Sulfonmethane 44
(11) Ketamine hydrochloride 45

S191 POLISTINA
3

(12) Except when acquired, prescribed, administered, or 1
dispensed by a veterinarian in the course of the professional 2
practice of veterinary medicine, any of the following substances, 3
including their salts, isomers, and salts of isomers whenever the 4
existence of such salts, isomers, or salts of isomers is possible with 5
the specific chemical designation: xylazine; xylazine-M (2,6Mich 6
dimethylaniline); xylazine-M (N-thiourea-2,6-dimethylaniline); 7
xylazine-M (sulfone-HO-) isomer 2; xylazine-M (HO-2,6-8
dimethylaniline isomer 1); xylazine-M (HO-2,6-dimethylaniline 9
isomer 2); xylazine-M (oxo-); xylazine-M (HO-) isomer 1; 10
xylazine-M (HO-) isomer1 glucuronide; xylazine-M (HO-) isomer 11
2; xylazine-M (HO-) isomer 2 glucuronide; xylazine-M (HO-oxo-) 12
isomer 1; xylazine-M (HO-oxo-) isomer 1 glucuronide; xylazine-M 13
(HO-oxo-) isomer 2; xylazine-M (HO-oxo-) isomer 2 glucuronide; 14
xylazine-M (sulfone); xylazine-M (sulfone-HO-) isomer 1; and any 15
compound, mixture, or preparation that contains any quantity of any 16
of the substances listed in this paragraph. 17
e. Nalorphine. 18
f. Any material, compound, mixture, or preparation containing 19
limited quantities of any of the following narcotic drugs, or any 20
salts thereof: 21
(1) Not more than 1.80 grams of codeine or any of its salts per 22
100 milliliters or not more than 90 milligrams per dosage unit, with 23
an equal or greater quantity of an isoquinoline alkaloid of opium. 24
(2) Not more than 1.80 grams of codeine or any of its salts per 25
100 milliliters or not more than 90 milligrams per dosage unit, with 26
one or more active, nonnarcotic ingredients in recognized 27
therapeutic amounts. 28
(3) Not more than 300 milligrams of dihydrocodeinone or any of 29
its salts per 100 milliliters or not more than 15 milligrams per 30
dosage unit, with a four-fold or greater quantity of an isoquinoline 31
alkaloid of opium. 32
(4) Not more than 300 milligrams of dihydrocodeinone or any of 33
its salts per 100 milliliters or not more than 15 milligrams per 34
dosage unit, with one or more active, nonnarcotic ingredients in 35
recognized therapeutic amounts. 36
(5) Not more than 1.80 grams of dihydrocodeine or any of its 37
salts per 100 milliliters or not more than 90 milligrams per dosage 38
unit, with one or more active, nonnarcoti